Cancer Prof: Industry views on targeted oncotherapies 'misplaced'’
This article was originally published in Scrip
"The idea that targeted therapy will replace chemotherapy across cancer is just as misplaced as the view 20 years ago that drug treatments would replace surgery." That opinion, expressed at the 2013 European Cancer Congress in Amsterdam by Professor Christopher Twelves, a consultant in medical oncology at the University of Leeds, UK, is "not always well received by the industry," he says.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.